Search
Press Release: Better funding for research into blood diseases will save more lives
“Haematology is probably the area of medicine that has progressed the most in recent years”, said Professor Robin Foà of “La Sapienza” University of Rome.
Read morePieter Sonneveld appointed Officer in the Order of Orange-Nassau
The EHA Board congratulates former EHA President Professor Pieter Sonneveld on his appointment as an Officer of the Order of Orange-Nassau by His Majesty King Willem-Alexander of the Netherlands.
Read moreThe HARMONY project: learning to work in BIG (DATA) teams
The HARMONY project: learning to work in BIG (DATA) teams
By Anna Kabanova PhD, YoungEHA committee member
On 26 and 27 September 2019 several YoungEHA members, including myself, had the chance to participate in the 4th General Assembly of the HARMONY Alliance…
Meet Maria-Victoria Mateos, our April Volunteer of the Month
Maria Victoria Mateos currently heads the Scientific Program Committee of the 24th EHA Congress which will be held on June 13-16 in Amsterdam.
Read moreMeet Maria-Victoria Mateos, our April Volunteer of the Month
Maria Victoria Mateos currently heads the Scientific Program Committee of the 24th EHA Congress which will be held on June 13-16 in Amsterdam.
Read moreMeet our Volunteers of the Month: Elizabeth, Francesca and Verena
Yes, you read that right. For this month, we have more than one Volunteer of the Month: Elizabeth Macintyre, Francesca Vinchi and Verena Gaidzik.
Read moreMeet our Volunteers of the Month: Elizabeth, Francesca and Verena
Yes, you read that right. For this month, we have more than one Volunteer of the Month: Elizabeth Macintyre, Francesca Vinchi and Verena Gaidzik.
Read morePRESS RELEASE: The future of research in hematology is here
“For the first time, hematologists in Europe came together to develop a roadmap to guide hematology research in Europe” says Professor Andreas Engert, chair of the EHA Research Roadmap Task Force, “Hematology in Europe has achieved a lot, but the discipline must focus and…
Read moreTargeting the B-cell Receptor in Aggressive B-cell Lymphomas
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.
Read moreAcute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab
The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- »